About Us

GeneCentric’s mission is to become a leader in the development and commercialization of biomarkers and companion diagnostics that define cancer drug responders and drive success in drug development.

We apply our proprietary rT(I)ME Explorer Platform to identify RNA-based gene signatures in the form of molecular subtypes and drug response predictors that enable the development of precision cancer drugs while improving patient outcomes.

Our approach yields high-resolution gene signatures that are prognostic or predictive and applies them to immune-based, targeted and other cancer therapeutics. By commercializing our technology through strategic collaborations with diagnostics, pharmaceutical and biotechnology companies, we are continuously growing our pipeline of gene signatures and related diagnostics.

 

Michael V. Milburn, PhD

Chief Executive Officer and President




Kirk_Beebe

Kirk Beebe, PhD

Chief Scientific Officer




Chenyqua Shepard, CPA

Chief Operating Officer




Joel R. Eisner, PhD

Sr. Vice President - Clinical & Corporate Development




Brian Kelly

Sr. Vice President – Business Development




Myla Lai-Goldman, MD

Founder & Executive Chairperson

Arnold J. Levine, Phd

Director

Michael V. Milburn, PhD

Chief Executive Officer and President

Charles M. Perou, PhD

Founder and Director

Clay B. Thorp

General Partner, Hatteras Venture Partners

N. Hayes

David Neil Hayes, MD MPH MS

Observer and Founder

Prasanth Reddy, MD, MPH, FACP

Director

Don M. Hardison

Director